| # | Title | Journal | Year | Citations |
|---|
| 1 | Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2018 | 2,676 |
| 2 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
| 3 | Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer | New England Journal of Medicine | 2002 | 1,298 |
| 4 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 1,202 |
| 5 | A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) | Annals of Surgical Oncology | 2012 | 1,152 |
| 6 | Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) | Lancet, The | 2016 | 799 |
| 7 | Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer | Nature Medicine | 2019 | 773 |
| 8 | Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | British Journal of Cancer | 2010 | 620 |
| 9 | Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria | Surgery Today | 2016 | 541 |
| 10 | Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial | Lancet, The | 2022 | 537 |
| 11 | A Phase III Randomized Trial of Lobectomy Versus Limited Resection for Small-sized Peripheral Non-small Cell Lung Cancer (JCOG0802/WJOG4607L) | Japanese Journal of Clinical Oncology | 2010 | 497 |
| 12 | Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial | Lancet Oncology, The | 2019 | 470 |
| 13 | Directional cell movement through tissues is controlled by exosome secretion | Nature Communications | 2015 | 457 |
| 14 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2022 | 445 |
| 15 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study | Journal of Clinical Oncology | 2020 | 410 |
| 16 | CT-guided needle biopsy of lung lesions: A survey of severe complication based on 9783 biopsies in Japan | European Journal of Radiology | 2006 | 404 |
| 17 | Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection | PLoS ONE | 2011 | 356 |
| 18 | KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes | Cell Reports | 2016 | 328 |
| 19 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC | Journal of Thoracic Oncology | 2020 | 328 |
| 20 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial | Journal of Thoracic Oncology | 2021 | 323 |
| 21 | Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212) | Annals of Surgery | 2017 | 322 |
| 22 | Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy | Gastroenterology | 2011 | 304 |
| 23 | Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial | Lancet Oncology, The | 2012 | 300 |
| 24 | Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703) | Gastric Cancer | 2010 | 297 |
| 25 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies | International Journal of Cancer | 2020 | 288 |
| 26 | Appropriate Sublobar Resection Choice for Ground Glass Opacity-Dominant Clinical Stage IA Lung Adenocarcinoma | Chest | 2014 | 280 |
| 27 | Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201 | Journal of Thoracic and Cardiovascular Surgery | 2013 | 279 |
| 28 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 | Annals of Oncology | 2021 | 279 |
| 29 | Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial | Journal of Clinical Oncology | 2019 | 258 |
| 30 | Cortactin promotes exosome secretion by controlling branched actin dynamics | Journal of Cell Biology | 2016 | 226 |
| 31 | Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study | The Lancet Gastroenterology and Hepatology | 2019 | 223 |
| 32 | Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients | World Journal of Surgery | 2012 | 219 |
| 33 | Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer | Investigational New Drugs | 2012 | 213 |
| 34 | Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies | Nature Medicine | 2020 | 209 |
| 35 | Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients | Leukemia | 2014 | 199 |
| 36 | Comprehensive mutational analysis of theVHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters | Genes Chromosomes and Cancer | 2002 | 197 |
| 37 | Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort | Journal of Thoracic Oncology | 2011 | 196 |
| 38 | Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter study | Journal of Thoracic and Cardiovascular Surgery | 2012 | 195 |
| 39 | Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial | Annals of Oncology | 2019 | 195 |
| 40 | Chemotherapy for hepatocellular carcinoma: current status and future perspectives | Japanese Journal of Clinical Oncology | 2018 | 192 |
| 41 | Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study | Lancet Oncology, The | 2015 | 191 |
| 42 | Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) | Clinical Cancer Research | 2019 | 191 |
| 43 | Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer | Cancer Research | 2009 | 190 |
| 44 | Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study | Journal of Thoracic Oncology | 2016 | 184 |
| 45 | Dikkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas | Cancer Research | 2007 | 181 |
| 46 | Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer | Clinical Cancer Research | 2008 | 179 |
| 47 | Therapeutic Strategy for Differentiated Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons | World Journal of Surgery | 2011 | 179 |
| 48 | Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: Propensity score–matched analysis in a multicenter study | Journal of Thoracic and Cardiovascular Surgery | 2013 | 176 |
| 49 | Is gastric carcinoma different between Japan and the United States? | Cancer | 2000 | 174 |
| 50 | Effects of a Diverting Stoma on Symptomatic Anastomotic Leakage after Low Anterior Resection for Rectal Cancer: A Propensity Score Matching Analysis of 1,014 Consecutive Patients | Journal of the American College of Surgeons | 2015 | 161 |
